ATC code M: Difference between revisions
Content deleted Content added
No edit summary Tag: Reverted |
m Task 5: remove this page from Category:Long monitored short pages |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
{{Major drug groups}} |
{{Major drug groups}} |
||
{{Anti-inflammatory products}} |
|||
{{Antirheumatic products}} |
|||
| ⚫ | |||
{{Topical products for joint and muscular pain}} |
|||
{{Muscle relaxants}} |
|||
{{Antigout preparations}} |
|||
{{Drugs for treatment of bone diseases}} |
|||
{{Other drugs for disorders of the musculo-skeletal system}} |
|||
| ⚫ | |||
Latest revision as of 23:04, 26 May 2022
| ATC code M: Musculo-skeletal system |
|---|
|
| Other ATC codes |
ATC code M Musculo-skeletal system is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QM.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
[edit]- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code M". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QM". WHO Collaborating Centre for Drug Statistics Methodology.
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System | |
|---|---|
| gastrointestinal tract / metabolism (A) | |
| blood and blood forming organs (B) | |
| cardiovascular system (C) | |
| skin (D) | |
| genitourinary system (G) | |
| endocrine system (H) | |
| infections and infestations (J, P, QI) | |
| malignant disease (L01–L02) | |
| immune disease (L03–L04) | |
| muscles, bones, and joints (M) | |
| brain and nervous system (N) |
|
| respiratory system (R) | |
| sensory organs (S) | |
| other ATC (V) | |
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
